Introduction: Although some studies have shown elevated soluble interleukin 2 receptor (sIL-2R) in sera of patients with hematological malignancies and some autoimmune diseases, its role in serum is not fully understood.
Patients and methods: The aim was to compare serum levels of sIL-2R in four groups of women (11 with Graves disease, 10 with Hashimotos thyroiditis, 11 with breast cancer and 10 healthy controls) and to test their possible relationship to parameters of thyroid function (TSH, FT4), thyroid antibodies (against thyroid peroxidase-TPOAb, thyroglobulin-TgAb and TSH receptor-TRAK) and thyroid volume. Serum levels of sIL-2R were measured using a commercially available ELISA kit, the other parameters using routine laboratory methods. All subjects underwent thyroid ultrasonography (Phillips Envisor) with measurement of thyroid volume.
Results: Serum levels of sIL-2R were significantly higher in women with Graves disease compared to Hashimotos thyroiditis (1.46±0.50 vs. 0.833±0.184 ng/ml, P<0.001), breast cancer (1.46±0.50 vs. 0.91±0.51, P=0.021) and controls (1.46±0.50 vs. 0.81±0.21, P=0.016). In the whole group, strong positive correlations between sIL-2R and FT4 (r=0.688, P=0.00000357, n=42) and sIL-2R and thyroid volume (r=0.636, P=0.000363, n=42) were found. No significant correlations were found between sIL-2R and TPOAb, TgAb and TRAK.
Conclusions: The close relation of sIL-2R to FT4 suggests that serum sIL-2R is rather the consequence of changes of thyroid function than thyroid autoimmunity. In contrast to hematological malignancies, sIL-2R was not elevated in sera of women with breast cancer.
Supported by grant IGANR8130-3.
01 - 05 Apr 2006
European Society of Endocrinology